AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month

The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD), AstraZeneca said.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/zcfgi1B
via